FibroBiologics Inc
Research FibroBiologics Inc (FBLG) on Bullrun: market cap USD 8.51M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerFBLG
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 8.51M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 4.12M
- Free cash flow-USD 3.29M
Valuation Snapshot
latest market cap is USD 8.51M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 18.65M | -USD 16.66M | n/a | -0.42 | USD 4.89M | USD 2.41M | USD 6.16M |
| FY2024 | USD 0 | -USD 11.16M | -USD 12.09M | n/a | -0.34 | USD 13.99M | USD 10.55M | USD 2.74M |
| FY2023 | n/a | -USD 16.49M | -USD 6.90M | n/a | -0.68 | USD 9.16M | USD 1.75M | USD 1.25M |
| FY2022 | n/a | -USD 5.12M | n/a | n/a | -0.18 | USD 2.27M | USD 60.00K | -USD 4.00M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 8.51M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 14.97M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 70.17M | n/a | n/a | n/a |
About FibroBiologics Inc
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is FibroBiologics Inc's market cap?
FibroBiologics Inc's market capitalization is USD 8.51M.
What does FibroBiologics Inc do?
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis.